1	Isotype-specific	_	JJ	_	_	2	NMOD	_	_
2	inhibitors	_	NNS	_	_	13	VMOD	_	_
3	of	_	IN	_	_	2	NMOD	_	_
4	the	_	DT	_	_	7	NMOD	_	_
5	glycolytic	_	JJ	_	_	7	NMOD	_	_
6	key	_	JJ	_	_	7	NMOD	_	_
7	regulator	_	NN	_	_	11	NMOD	_	_
8	pyruvate	_	NN	_	_	11	NMOD	_	_
9	kinase	_	NN	_	_	11	NMOD	_	_
10	subtype	_	NN	_	_	11	NMOD	_	_
11	M2	_	NN	_	_	3	PMOD	_	_
12	moderately	_	RB	_	_	13	VMOD	_	_
13	decelerate	_	VBP	_	_	0	ROOT	_	_
14	tumor	_	NN	_	_	16	NMOD	_	_
15	cell	_	NN	_	_	16	NMOD	_	_
16	proliferation	_	NN	_	_	13	VMOD	_	_
17	.	_	.	_	_	13	P	_	_
		
1	Tumor	_	NN	_	_	2	NMOD	_	_
2	cells	_	NNS	_	_	3	VMOD	_	_
3	express	_	VBP	_	_	0	ROOT	_	_
4	the	_	DT	_	_	10	NMOD	_	_
5	glycolytic	_	JJ	_	_	10	NMOD	_	_
6	regulator	_	NN	_	_	10	NMOD	_	_
7	pyruvate	_	NN	_	_	10	NMOD	_	_
8	kinase	_	NN	_	_	10	NMOD	_	_
9	subtype	_	NN	_	_	10	NMOD	_	_
10	M2	_	NN	_	_	3	VMOD	_	_
11	(	_	(	_	_	12	P	_	_
12	M2-PK	_	NN	_	_	10	PRN	_	_
13	)	_	)	_	_	12	P	_	_
14	,	_	,	_	_	10	P	_	_
15	which	_	WDT	_	_	16	VMOD	_	_
16	can	_	MD	_	_	10	NMOD	_	_
17	occur	_	VB	_	_	16	VC	_	_
18	in	_	IN	_	_	17	VMOD	_	_
19	a	_	DT	_	_	21	NMOD	_	_
20	tetrameric	_	JJ	_	_	21	NMOD	_	_
21	form	_	NN	_	_	18	PMOD	_	_
22	with	_	IN	_	_	21	NMOD	_	_
23	high	_	JJ	_	_	24	NMOD	_	_
24	affinity	_	NN	_	_	22	PMOD	_	_
25	to	_	TO	_	_	24	NMOD	_	_
26	its	_	PRP$	_	_	28	NMOD	_	_
27	substrate	_	NN	_	_	28	NMOD	_	_
28	phosphoenolpyruvate	_	NN	_	_	25	PMOD	_	_
29	(	_	(	_	_	30	P	_	_
30	PEP	_	NN	_	_	28	PRN	_	_
31	)	_	)	_	_	30	P	_	_
32	and	_	CC	_	_	21	COORD	_	_
33	a	_	DT	_	_	35	NMOD	_	_
34	dimeric	_	JJ	_	_	35	NMOD	_	_
35	form	_	NN	_	_	32	CONJ	_	_
36	with	_	IN	_	_	35	NMOD	_	_
37	a	_	DT	_	_	40	NMOD	_	_
38	low	_	JJ	_	_	40	NMOD	_	_
39	PEP	_	NN	_	_	40	NMOD	_	_
40	affinity	_	NN	_	_	36	PMOD	_	_
41	.	_	.	_	_	3	P	_	_
		
1	The	_	DT	_	_	2	NMOD	_	_
2	transition	_	NN	_	_	6	VMOD	_	_
3	between	_	IN	_	_	2	NMOD	_	_
4	both	_	DT	_	_	5	NMOD	_	_
5	conformations	_	NNS	_	_	3	PMOD	_	_
6	contributes	_	VBZ	_	_	0	ROOT	_	_
7	to	_	TO	_	_	6	VMOD	_	_
8	the	_	DT	_	_	9	NMOD	_	_
9	control	_	NN	_	_	7	PMOD	_	_
10	of	_	IN	_	_	9	NMOD	_	_
11	glycolysis	_	NN	_	_	10	PMOD	_	_
12	and	_	CC	_	_	6	COORD	_	_
13	is	_	VBZ	_	_	12	CONJ	_	_
14	important	_	JJ	_	_	13	VMOD	_	_
15	for	_	IN	_	_	14	AMOD	_	_
16	tumor	_	NN	_	_	17	NMOD	_	_
17	cell	_	NN	_	_	15	PMOD	_	_
18	proliferation	_	NN	_	_	17	NMOD	_	_
19	and	_	CC	_	_	18	COORD	_	_
20	survival	_	NN	_	_	19	CONJ	_	_
21	.	_	.	_	_	6	P	_	_
		
1	Here	_	RB	_	_	3	VMOD	_	_
2	we	_	PRP	_	_	3	VMOD	_	_
3	targeted	_	VBN	_	_	0	ROOT	_	_
4	M2-PK	_	NN	_	_	3	VMOD	_	_
5	by	_	IN	_	_	3	VMOD	_	_
6	synthetic	_	JJ	_	_	8	NMOD	_	_
7	peptide	_	NN	_	_	8	NMOD	_	_
8	aptamers	_	NNS	_	_	5	PMOD	_	_
9	,	_	,	_	_	8	P	_	_
10	which	_	WDT	_	_	12	VMOD	_	_
11	specifically	_	RB	_	_	12	VMOD	_	_
12	bind	_	VBP	_	_	8	NMOD	_	_
13	to	_	TO	_	_	12	VMOD	_	_
14	M2-PK	_	NN	_	_	13	PMOD	_	_
15	and	_	CC	_	_	12	COORD	_	_
16	shift	_	VB	_	_	15	CONJ	_	_
17	the	_	DT	_	_	18	NMOD	_	_
18	isoenzyme	_	NN	_	_	16	VMOD	_	_
19	into	_	IN	_	_	18	NMOD	_	_
20	its	_	PRP$	_	_	22	NMOD	_	_
21	low	_	JJ	_	_	22	NMOD	_	_
22	affinity	_	NN	_	_	24	NMOD	_	_
23	dimeric	_	JJ	_	_	24	NMOD	_	_
24	conformation	_	NN	_	_	19	PMOD	_	_
25	.	_	.	_	_	3	P	_	_
		
1	The	_	DT	_	_	3	NMOD	_	_
2	aptamer-induced	_	JJ	_	_	3	NMOD	_	_
3	dimerization	_	NN	_	_	8	VMOD	_	_
4	and	_	CC	_	_	3	COORD	_	_
5	inactivation	_	NN	_	_	4	CONJ	_	_
6	of	_	IN	_	_	3	NMOD	_	_
7	M2-PK	_	NN	_	_	6	PMOD	_	_
8	led	_	VBD	_	_	0	ROOT	_	_
9	to	_	TO	_	_	8	VMOD	_	_
10	a	_	DT	_	_	12	NMOD	_	_
11	significant	_	JJ	_	_	12	NMOD	_	_
12	decrease	_	NN	_	_	9	PMOD	_	_
13	in	_	IN	_	_	12	NMOD	_	_
14	the	_	DT	_	_	17	NMOD	_	_
15	PK	_	NN	_	_	17	NMOD	_	_
16	mass-action	_	JJ	_	_	17	NMOD	_	_
17	ratio	_	NN	_	_	13	PMOD	_	_
18	as	_	RB	_	_	17	COORD	_	_
19	well	_	RB	_	_	18	DEP	_	_
20	as	_	IN	_	_	18	DEP	_	_
21	ATP:ADP	_	NN	_	_	22	NMOD	_	_
22	ratio	_	NN	_	_	18	CONJ	_	_
23	in	_	IN	_	_	22	NMOD	_	_
24	the	_	DT	_	_	26	NMOD	_	_
25	target	_	NN	_	_	26	NMOD	_	_
26	cells	_	NNS	_	_	23	PMOD	_	_
27	.	_	.	_	_	8	P	_	_
		
1	Furthermore	_	RB	_	_	10	VMOD	_	_
2	,	_	,	_	_	10	P	_	_
3	the	_	DT	_	_	4	NMOD	_	_
4	expression	_	NN	_	_	10	VMOD	_	_
5	of	_	IN	_	_	4	NMOD	_	_
6	M2-PK-binding	_	JJ	_	_	8	NMOD	_	_
7	peptide	_	NN	_	_	8	NMOD	_	_
8	aptamers	_	NNS	_	_	5	PMOD	_	_
9	moderately	_	RB	_	_	10	VMOD	_	_
10	reduced	_	VBD	_	_	0	ROOT	_	_
11	the	_	DT	_	_	12	NMOD	_	_
12	growth	_	NN	_	_	10	VMOD	_	_
13	of	_	IN	_	_	12	NMOD	_	_
14	immortalized	_	VBN	_	_	17	NMOD	_	_
15	NIH3T3	_	NN	_	_	17	NMOD	_	_
16	cell	_	NN	_	_	17	NMOD	_	_
17	populations	_	NNS	_	_	13	PMOD	_	_
18	by	_	IN	_	_	10	VMOD	_	_
19	decelerating	_	NN	_	_	21	NMOD	_	_
20	cell	_	NN	_	_	21	NMOD	_	_
21	proliferation	_	NN	_	_	18	PMOD	_	_
22	,	_	,	_	_	18	P	_	_
23	but	_	CC	_	_	18	COORD	_	_
24	without	_	IN	_	_	23	CONJ	_	_
25	affecting	_	VBG	_	_	24	PMOD	_	_
26	apoptotic	_	JJ	_	_	28	NMOD	_	_
27	cell	_	NN	_	_	28	NMOD	_	_
28	death	_	NN	_	_	25	VMOD	_	_
29	.	_	.	_	_	10	P	_	_
		
1	Moreover	_	RB	_	_	8	VMOD	_	_
2	,	_	,	_	_	8	P	_	_
3	the	_	DT	_	_	6	NMOD	_	_
4	M2-PK-binding	_	JJ	_	_	6	NMOD	_	_
5	peptide	_	NN	_	_	6	NMOD	_	_
6	aptamers	_	NNS	_	_	8	VMOD	_	_
7	also	_	RB	_	_	8	VMOD	_	_
8	reduced	_	VBD	_	_	0	ROOT	_	_
9	the	_	DT	_	_	11	NMOD	_	_
10	proliferation	_	NN	_	_	11	NMOD	_	_
11	rate	_	NN	_	_	8	VMOD	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	human	_	JJ	_	_	17	NMOD	_	_
14	U-2	_	NN	_	_	17	NMOD	_	_
15	OS	_	NN	_	_	17	NMOD	_	_
16	osteosarcoma	_	NN	_	_	17	NMOD	_	_
17	cells	_	NNS	_	_	12	PMOD	_	_
18	.	_	.	_	_	8	P	_	_
		
1	In	_	IN	_	_	7	VMOD	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	present	_	JJ	_	_	4	NMOD	_	_
4	study	_	NN	_	_	1	PMOD	_	_
5	,	_	,	_	_	7	P	_	_
6	we	_	PRP	_	_	7	VMOD	_	_
7	developed	_	VBD	_	_	0	ROOT	_	_
8	the	_	DT	_	_	11	NMOD	_	_
9	first	_	JJ	_	_	11	NMOD	_	_
10	specific	_	JJ	_	_	11	NMOD	_	_
11	inhibitors	_	NNS	_	_	7	VMOD	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	the	_	DT	_	_	18	NMOD	_	_
14	pyruvate	_	NN	_	_	18	NMOD	_	_
15	kinase	_	NN	_	_	18	NMOD	_	_
16	isoenzyme	_	NN	_	_	18	NMOD	_	_
17	type	_	NN	_	_	18	NMOD	_	_
18	M2	_	NN	_	_	12	PMOD	_	_
19	and	_	CC	_	_	7	COORD	_	_
20	present	_	VBP	_	_	19	CONJ	_	_
21	evidence	_	NN	_	_	20	VMOD	_	_
22	that	_	IN	_	_	21	NMOD	_	_
23	these	_	DT	_	_	24	NMOD	_	_
24	inhibitors	_	NNS	_	_	26	VMOD	_	_
25	moderately	_	RB	_	_	26	VMOD	_	_
26	decelerate	_	VBP	_	_	22	SUB	_	_
27	tumor	_	NN	_	_	29	NMOD	_	_
28	cell	_	NN	_	_	29	NMOD	_	_
29	proliferation	_	NN	_	_	26	VMOD	_	_
30	.	_	.	_	_	7	P	_	_
		
